No Data
No Data
Mirum Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Mirum Pharmaceuticals' Volixibat Gets Breakthrough Therapy Designation From FDA
Express News | Mirum Pharmaceuticals Inc: Confirmatory Portion of Study Is Ongoing With Completion of Enrollment Expected in 2026
Express News | Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis